Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)

被引：8
|
作者：
Tsurutani, J. [1 ]
Jacot, W. [2 ]
Yamashita, T. [3 ]
Riaz, F. [4 ]
Yerushalmi, R. [5 ]
Im, S-A. [6 ]
Niikura, N. [7 ]
Halser-Strub, U. [8 ]
Cortes, J. [9 ,10 ]
Wennstig, A-K. [11 ]
Chae, Y. [12 ]
Wang, X. [13 ]
Li, W. [14 ]
Simon, H. [15 ]
Masci, G. [16 ]
Tamburini, E. [17 ]
Aguilar, C. Orbegoso [18 ]
Tecson, K. [19 ]
Yung, L. [20 ]
Modi, S. [21 ]
机构：
[1] Showa Univ Hosp, Adv Canc Translat Res Inst, Tokyo, Japan
[2] Inst Canc Montpellier, Med Oncol, Montpellier, France
[3] Kanagawa Canc Ctr, Breast Surg & Oncol, Yokohama, Kanagawa, Japan
[4] Stanford Sch Med, Med Oncol, Stanford, CA USA
[5] Tel Aviv Univ, Inst Oncol, Davidoff Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[7] Tokai Univ, Breast Oncol, Sch Med, Isehara, Kanagawa, Japan
[8] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland
[9] Int Breast Canc Ctr, Oncol, Pangaea Oncol, Quironsalud Grp, Madrid, Spain
[10] Int Breast Canc Ctr, Oncol, Pangaea Oncol, Quironsalud Grp, Barcelona, Spain
[11] Sundsvall Hosp, Oncol, Sundsvall, Sweden
[12] Kyungpook Natl Univ, Med Oncol, Chilgok Hosp, Daegu, South Korea
[13] Zhejiang Canc Hosp, Med Oncol, Canc Res Inst, Hangzhou, Peoples R China
[14] First Hosp Jilin Univ, Tumor Ctr, Changchun, Jilin, Peoples R China
[15] CHU Brest, Oncol, Hop Morvan, Inst Cancerol & Hematol, Brest, France
[16] Humanitas Clin Res Hosp Rozzano, Med Oncol, Rozzano, MI, Italy
[17] Pia Fdn Cardinale G Panico Hosp, Oncol & Palliat Care, Tricase, Italy
[18] Daiichi Sankyo France SAS, Global Oncol R&D, Rueil Malmaison, France
[19] Daiichi Sankyo Inc, Evidence Generat, Basking Ridge, NJ USA
[20] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA
[21] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388P
引用
收藏
页码：S342 / S343
页数：2
相关论文
共 50 条
  • [1] Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Ueno, N. T.
    Jacot, W.
    Yamashita, T.
    Sohn, J.
    Tokunaga, E.
    Prat, A.
    Tsurutani, J.
    Park, Y. H.
    Rugo, H. S.
    Xu, B.
    Cardoso, F.
    Mitri, Z.
    Mahtani, R.
    Dunton, K.
    Wang, Y.
    Gambhire, D.
    Cottone, F.
    Harbeck, N.
    Cameron, D. A.
    Modi, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S633
  • [2] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
    Modi, S.
    Jacot, W.
    Iwata, H.
    Park, Y. H.
    Vidal Losada, M. J.
    Li, W.
    Tsurutani, J.
    Zaman, K.
    Ueno, N. T.
    Prat, A.
    Papazisis, K.
    Rugo, H. S.
    Harbeck, N.
    Im, S-A.
    De Laurentiis, M.
    Orbegoso, C. M. A.
    Yung, L.
    Cheng, F-C.
    Cheng, Y.
    Cameron, D. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S334 - S335
  • [3] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Wang, Xiaojia
    Xu, Binghe
    Gambhire, Dhiraj
    Yung, Lotus
    Meinhardt, Gerold
    Wang, Yibin
    Harbeck, Nadia
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [4] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04
    Modi, Shanu
    Niikura, Naoki
    Yamashita, Toshinari
    Jacot, William
    Sohn, Joohyuk
    Tokunaga, Eriko
    Vidal, Maria Jesus
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yeesoo
    Ueno, Naoto T.
    Prat, Aleix
    Suto, Fumitaka
    Kuwahara, Yusuke
    McEwen, Robert
    Feng, Wenqin
    Goto, Hiroki
    Orbegoso, Cecilia
    Cameron, David A.
    Tsurutani, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
    Harbeck, Nadia
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Vidal, Maria
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Niikura, Naoki
    Xu, Binghe
    Rugo, Hope
    Papazisis, Konstantinos
    Cortes, Javier
    Krop, Ian
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Cameron, David
    CANCER RESEARCH, 2023, 83 (05)
  • [6] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04
    Tsurutani, Junji
    Modi, Shanu
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Niikura, Naoki
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yee Soo
    Wang, Xiaojia
    Li, Wei
    Im, Seock-Ah
    Xu, Binghe
    Lu, Yen-Shen
    Gambhire, Dhiraj
    Nishijima, Soichiro
    Nishiyama, Yuji
    Sugihara, Masahiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1379 - S1379
  • [7] Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Niikura, Naoki
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yee Soo
    Xu, Binghe
    Wang, Xiaojia
    Im, Seock-Ah
    Li, Wei
    Lu, Yen-Shen
    Aguilar, Cecilia Orbegoso
    Nishijima, Soichiro
    Nishiyama, Yuji
    Sugihara, Masahiro
    Modi, Shanu
    Tsurutani, Junji
    BREAST CANCER, 2024, 31 (05) : 858 - 868
  • [8] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [9] A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Zaman, K.
    Modi, S.
    Ohtan, S.
    Lee, C.
    Wang, Y.
    Saxena, K.
    Cameron, D. A.
    SWISS MEDICAL WEEKLY, 2020, : 28S - 29S
  • [10] Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Ueno, N. T.
    Niikura, N.
    Yamashita, T.
    Jacot, W.
    Cameron, D. A.
    Tsurutani, J.
    Sohn, J.
    Tokunaga, E.
    Vidal Losada, M. J.
    Park, Y. H.
    Lee, K. S.
    Chae, Y. S.
    Prat, A.
    Suto, F.
    Kuwahara, Y.
    Boran, A. D.
    Kobayashi, M.
    Kumar, V.
    Aguilar, C. Orbegoso
    Modi, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S401 - S402
12345